| Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. | |
| | |
MedLine Citation:
|
PMID: 2248508 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Seventy-three children with steroid dependent minimal change nephrotic syndrome were randomly allocated to receive treatment with cyclophosphamide (2 mg/kg/day) for either eight or 12 weeks, in combination with prednisolone. All patients had previously relapsed while the dosage was being reduced or within 14 days of discontinuing prednisolone in the six months before receiving cyclophosphamide treatment (steroid dependent), and had severe steroid toxicity. Thirty two patients were treated with cyclophosphamide for eight weeks, and 41 for 12 weeks. There were no differences between the two groups in age at onset of nephrosis or entry into the study, sex ratio, duration of nephrosis, number of relapses before entry, and follow up period after entry. The relapse free rate of patients treated for eight weeks (25%) was similar to that of those treated for 12 weeks (24%) five years after stopping the treatment, and the mean relapse free interval and the sparing effect of cyclophosphamide (if any) on subsequent treatment with steroids did not differ between the groups. We conclude that cyclophosphamide should be used for no longer than eight weeks at a dose of 2 mg/kg/day in children with steroid dependent minimal change nephrotic syndrome. |
| | |
Authors:
|
N Ueda; K Kuno; S Ito |
Related Documents
:
|
10811328 - Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative co... 23223878 - Acromial morphology in patients with calcific tendinitis of the shoulder. 17822518 - Rehabilitation of synovitis in patients with haemophilia. 22929268 - Classification of trigonocephaly in metopic synostosis. 6146018 - Failure of proximal gastric vagotomy for duodenal ulcer resistant to cimetidine. 17938308 - Morbidity of anastomotic leaks in patients undergoing roux-en-y gastric bypass. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Archives of disease in childhood Volume: 65 ISSN: 1468-2044 ISO Abbreviation: Arch. Dis. Child. Publication Date: 1990 Oct |
Date Detail:
|
Created Date: 1991-01-07 Completed Date: 1991-01-07 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 0372434 Medline TA: Arch Dis Child Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1147-50 Citation Subset: AIM; IM |
Affiliation:
|
Department of Paediatrics, Fujita Gakuen Health University School of Medicine, Toyoake, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Child Cyclophosphamide / administration & dosage, therapeutic use* Dose-Response Relationship, Drug Drug Therapy, Combination Female Humans Male Nephrosis, Lipoid / drug therapy* Prednisolone / therapeutic use Prospective Studies Recurrence Time Factors |
| Chemical | |
Reg. No./Substance:
|
50-18-0/Cyclophosphamide; 50-24-8/Prednisolone |
| Comments/Corrections | |
Comment In:
|
Arch Dis Child. 1991 Jun;66(6):751
[PMID:
2053810
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Kawasaki disease: echocardiographic features in 91 cases presenting in the United Kingdom.
Next Document: Continuous papaveretum infusion for the control of pain in painful sickling crisis.